血清胆红素在慢性肾脏病患者中发挥保护作用的研究进展
摘要
胆红素是血红素的代谢产物,作为人体的一种重要内源性物质,长期以来被认为是一种有害物质,仅在升高时用于黄疸的诊断,也是肝功能的重要指标。近年来,有研究结果发现,胆红素具有抗氧化、抗炎、抗动脉粥样硬化等作用,对部分心血管疾病如高血压、冠心病、心功能不全以及缺血性脑血管病、代谢综合征均具有一定的防护作用,胆红素对慢性肾脏病(CKD)保护作用的研究引起了中外学者的重视。本文对胆红素抗氧化、抗炎作用及其在CKD患者中发挥保护作用的研究进展作一综述。
引文
[1]Bonnett R,Davis JE,Hurstyouse MB.Structure of Bilirubin[J].Nature,1976,262(5566):327-328.
[2]Ostrow JD,Mukerjee P,Tiribelli C,et al.Structure and binding of unconjugated bilirubin:relevance for physiological and pathophysiological function[J].J Lipid Res,1994,35(10):1715-1737.
[3]Abraham NG,Kappas A.Heme oxygenase and the cardiovascular-renal system[J].Free Radic Biol Med,2005,39(1):1-25.
[4]Stocker R,Yamamoto Y,Mc Donagh AF,et al.Bilirubin is an antioxidant of possible physiological importance[J].Science,1987,235(4792):1043-1046.
[5]David E,Rao M,Christopher D,et al.Biliverdin reductase:a major physiologic cytoprotectant[J].Proc Natl Acad Sci USA,2002,99(25):16093-16098.
[6]曹伟,邓宁.血清胆红素与冠心病冠状动脉病变程度相关性[J].辽宁医学杂志,2011,25(4):189-190.
[7]Jansen T,Hortmann M,Oelze M,et al.Conversion of biliverdin to bilirubin by biliverdin reductase contributes to endothelial cell protection by heme oxygenase-1-evidence for direct and indirect antioxidant actions of bilirubin[J].J Mol Cell Cardiol,2010,49(2):186-195.
[8]Ben-Amotz R,Bonagura J,Velayutham M,et al.Intraperitoneal bilirubin administration decreases infarct area in a rat coronary ischemia/reperfusion model[J].Front Physiol,2014,18(5):53.
[9]Wallner M,Bulmer AC,Molzer C,et al.Haeme catabolism:a novel modulator of inflammation in Gilbert’s syndrome[J].Eur J Clin Invest,2013,43(9):912-919.
[10]Fredenburgh LE,Merz AA,Cheng S.Haeme oxygenase signaling pathway:implications for cardiovascular disease[J].Eur Heart J,2015,36(24):1512-1518.
[11]Coresh J,Selvin E,Stevens LA,et al.Prevalence of chronic kidney disease in the united states[J].JAMA,2007,298:2038-2047.
[12]Hsu CY,Mc Culloch CE,Fan D,Ordonez JD,Chertow GM,Go AS.Community-based incidence of acute renal failure[J].Kidney Int,2007,72:208-212.
[13]Lanone S,Bloc S,Foresti R,et al.Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase:Implications for protection against endotoxic shock in rats[J].FASEB J,2005,19:1890-1892.
[14]Sano K,Nakamura H,Matsuo T.Mode of inhibitory action of bilirubin on protein kinase c[J].Pediatr Res,1985,19:587-590.
[15]Mietus-Snyder M,Friera A,Glass CK,Pitas RE.Regulation of scavenger receptor expression in smooth muscle cells by protein kinase c:A role for oxidative stress[J].Arterioscler Thromb Vasc Biol,1997,17:969-978.
[16]Koya D,King GL.Protein kinase c activation and the development of diabetic complications[J].Diabetes,1998,47:859-866.
[17]Roh DD,Kamanna VS,Kirschenbaum MA.Oxidative modification of low-density lipoprotein enhances mesangial cell protein synthesis and gene expression of extracellular matrix proteins[J].Am J Nephrol,1998,18:344-350.
[18]Suzuki D,Miyata T,Saotome N,et al.Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions[J].J Am Soc Nephrol,1999,10:822-832.
[19]Stehouwer CD,Gall MA,Twisk JW,et al.Increased urinary albumin excretion,endothelial dysfunction,and chronic low-grade inflammation in type 2 diabetes:Progressive,interrelated,and independently associated with risk of death[J].Diabetes,2002,51:1157-1165.
[20]张玲明,圈启芳,血清胆红素与糖尿病肾病的关系[J].糖尿病新世界,2016,11(12):130-133.
[21]Adin CA,Croker BP,Agarwal A.Protective effects of exogenousbilirubin on ischemia-reperfusion injury in the isolated,perfused ratkidney[J].Am J Physiol Renal Physiol,2005,288:778-784.
[22]Riphagen IJ,Deetman PE,Bakker SJL,et al.Bilirubin and progression of nephropathy in type 2 diabetes:a post-hoc analysis of RENAAL with independent replication in IDNT[J].Diabetes,2014,63:2845-2853.
[23]Sakoh T,Nakayama M,Tanaka S,et al.Association of serum total bilirubin with renal outcome in Japanese patients with stages 3-5 chronic kidney disease[J].Metabolism,2015,64:1096-1102.
[24]Fukui M,Tanaka M,Shiraishi E,et al.Relationship between serum bilirubin and albuminuria in patients with type 2 diabetes[J].Kidney Int,2008,74:1197-1201.
[25]Kumar A,Pant P,Basu S,Rao GR,and Khanna HD.Oxidative stress in neonatal hyperbilirubinemia[J].J Trop Pediatr,2007,53:69-71.
[26]Kao MP,Ang DS,Pall A,Struthers AD.Oxidative stress in renal dysfunction:mechanisms,clinical sequelae and therapeutic options[J].J Hum Hypertens,2010,24:1-8.
[27]Vera T,Stec DE.Moderate hyperbilirubinemia improves renal hemodynamics in ANG II-dependent hypertension[J].Am J Physiol Regul Integr Comp Physiol,2010,299:1044-1049.
[28]Vera T,Granger JP,Stec DE.Inhibition of bilirubin metabolism induces moderate hyperbilirubinemia and attenuates ANG II-dependent hypertension in mice[J].Am J Physiol Regul Integr Comp Physiol,2009,297:738-743.
[29]Nakagami T,Toyomura K,Kinoshita T,Morisawa S.A beneficial role of bile pigments as an endogenous tissue protector:Anti-complement effects of biliverdin and conjugated bilirubin[J].Biochim Biophys Acta,1993,1158:189-193.
[30]Mazzone GL,Rigato I,Ostrow JD,Bossi F,Bortoluzzi A,Sukowati CH,et al.Bilirubin inhibits the TNFalpha-related induction of three endothelial adhesion molecules[J].Biochem Biophys Res Commun,2009,386:338-344.
[31]Schwertner HA,Jackson WG,Tolan G.Association of low serum concentration of bilirubin with increased risk of coronary artery disease[J].Clin Chem,1994,40:18-23.
[32]Breimer LH,Wannamethee G,Ebrahim S,Shaper AG.Serum bilirubin and risk of ischemic heart disease in middle-aged British men[J].Clin Chem,1995,41:1504-1508.
[33]Vítek L,Jirsa M,BrodanováM,et al.Gilbert syndrome and ischemic heart disease:a protective effect of elevated bilirubin levels[J].Atherosclerosis,2002,160:449-456.
[34]Yilmaz MB,Biyikoglu SF,Akin Y,.Obesity is associated with impaired coronary collateral vessel development[J].Int J Obes,2003,27:1541-1545.
[35]Davignon J,Ganz P.Role of endothelial dysfunction in atherosclerosis[J].Ci rculation,2004,109:III27-32.
[36]Vanhoutte,P.M.The endothelium-modulator of vascular smooth-muscle tone[J].N Engl J Med,1988,319:512-513.
[37]Recio-Mayoral A,Banerjee D,Streather C.Endothelial dysfunction,inflammation and atherosclerosis in chronic kidney disease-a crosssectional study of predialysis,dialysis and kidney-transplantation patients[J].Atherosclerosis,2011,216:446-451.
[2]Ostrow JD,Mukerjee P,Tiribelli C,et al.Structure and binding of unconjugated bilirubin:relevance for physiological and pathophysiological function[J].J Lipid Res,1994,35(10):1715-1737.
[3]Abraham NG,Kappas A.Heme oxygenase and the cardiovascular-renal system[J].Free Radic Biol Med,2005,39(1):1-25.
[4]Stocker R,Yamamoto Y,Mc Donagh AF,et al.Bilirubin is an antioxidant of possible physiological importance[J].Science,1987,235(4792):1043-1046.
[5]David E,Rao M,Christopher D,et al.Biliverdin reductase:a major physiologic cytoprotectant[J].Proc Natl Acad Sci USA,2002,99(25):16093-16098.
[6]曹伟,邓宁.血清胆红素与冠心病冠状动脉病变程度相关性[J].辽宁医学杂志,2011,25(4):189-190.
[7]Jansen T,Hortmann M,Oelze M,et al.Conversion of biliverdin to bilirubin by biliverdin reductase contributes to endothelial cell protection by heme oxygenase-1-evidence for direct and indirect antioxidant actions of bilirubin[J].J Mol Cell Cardiol,2010,49(2):186-195.
[8]Ben-Amotz R,Bonagura J,Velayutham M,et al.Intraperitoneal bilirubin administration decreases infarct area in a rat coronary ischemia/reperfusion model[J].Front Physiol,2014,18(5):53.
[9]Wallner M,Bulmer AC,Molzer C,et al.Haeme catabolism:a novel modulator of inflammation in Gilbert’s syndrome[J].Eur J Clin Invest,2013,43(9):912-919.
[10]Fredenburgh LE,Merz AA,Cheng S.Haeme oxygenase signaling pathway:implications for cardiovascular disease[J].Eur Heart J,2015,36(24):1512-1518.
[11]Coresh J,Selvin E,Stevens LA,et al.Prevalence of chronic kidney disease in the united states[J].JAMA,2007,298:2038-2047.
[12]Hsu CY,Mc Culloch CE,Fan D,Ordonez JD,Chertow GM,Go AS.Community-based incidence of acute renal failure[J].Kidney Int,2007,72:208-212.
[13]Lanone S,Bloc S,Foresti R,et al.Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase:Implications for protection against endotoxic shock in rats[J].FASEB J,2005,19:1890-1892.
[14]Sano K,Nakamura H,Matsuo T.Mode of inhibitory action of bilirubin on protein kinase c[J].Pediatr Res,1985,19:587-590.
[15]Mietus-Snyder M,Friera A,Glass CK,Pitas RE.Regulation of scavenger receptor expression in smooth muscle cells by protein kinase c:A role for oxidative stress[J].Arterioscler Thromb Vasc Biol,1997,17:969-978.
[16]Koya D,King GL.Protein kinase c activation and the development of diabetic complications[J].Diabetes,1998,47:859-866.
[17]Roh DD,Kamanna VS,Kirschenbaum MA.Oxidative modification of low-density lipoprotein enhances mesangial cell protein synthesis and gene expression of extracellular matrix proteins[J].Am J Nephrol,1998,18:344-350.
[18]Suzuki D,Miyata T,Saotome N,et al.Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions[J].J Am Soc Nephrol,1999,10:822-832.
[19]Stehouwer CD,Gall MA,Twisk JW,et al.Increased urinary albumin excretion,endothelial dysfunction,and chronic low-grade inflammation in type 2 diabetes:Progressive,interrelated,and independently associated with risk of death[J].Diabetes,2002,51:1157-1165.
[20]张玲明,圈启芳,血清胆红素与糖尿病肾病的关系[J].糖尿病新世界,2016,11(12):130-133.
[21]Adin CA,Croker BP,Agarwal A.Protective effects of exogenousbilirubin on ischemia-reperfusion injury in the isolated,perfused ratkidney[J].Am J Physiol Renal Physiol,2005,288:778-784.
[22]Riphagen IJ,Deetman PE,Bakker SJL,et al.Bilirubin and progression of nephropathy in type 2 diabetes:a post-hoc analysis of RENAAL with independent replication in IDNT[J].Diabetes,2014,63:2845-2853.
[23]Sakoh T,Nakayama M,Tanaka S,et al.Association of serum total bilirubin with renal outcome in Japanese patients with stages 3-5 chronic kidney disease[J].Metabolism,2015,64:1096-1102.
[24]Fukui M,Tanaka M,Shiraishi E,et al.Relationship between serum bilirubin and albuminuria in patients with type 2 diabetes[J].Kidney Int,2008,74:1197-1201.
[25]Kumar A,Pant P,Basu S,Rao GR,and Khanna HD.Oxidative stress in neonatal hyperbilirubinemia[J].J Trop Pediatr,2007,53:69-71.
[26]Kao MP,Ang DS,Pall A,Struthers AD.Oxidative stress in renal dysfunction:mechanisms,clinical sequelae and therapeutic options[J].J Hum Hypertens,2010,24:1-8.
[27]Vera T,Stec DE.Moderate hyperbilirubinemia improves renal hemodynamics in ANG II-dependent hypertension[J].Am J Physiol Regul Integr Comp Physiol,2010,299:1044-1049.
[28]Vera T,Granger JP,Stec DE.Inhibition of bilirubin metabolism induces moderate hyperbilirubinemia and attenuates ANG II-dependent hypertension in mice[J].Am J Physiol Regul Integr Comp Physiol,2009,297:738-743.
[29]Nakagami T,Toyomura K,Kinoshita T,Morisawa S.A beneficial role of bile pigments as an endogenous tissue protector:Anti-complement effects of biliverdin and conjugated bilirubin[J].Biochim Biophys Acta,1993,1158:189-193.
[30]Mazzone GL,Rigato I,Ostrow JD,Bossi F,Bortoluzzi A,Sukowati CH,et al.Bilirubin inhibits the TNFalpha-related induction of three endothelial adhesion molecules[J].Biochem Biophys Res Commun,2009,386:338-344.
[31]Schwertner HA,Jackson WG,Tolan G.Association of low serum concentration of bilirubin with increased risk of coronary artery disease[J].Clin Chem,1994,40:18-23.
[32]Breimer LH,Wannamethee G,Ebrahim S,Shaper AG.Serum bilirubin and risk of ischemic heart disease in middle-aged British men[J].Clin Chem,1995,41:1504-1508.
[33]Vítek L,Jirsa M,BrodanováM,et al.Gilbert syndrome and ischemic heart disease:a protective effect of elevated bilirubin levels[J].Atherosclerosis,2002,160:449-456.
[34]Yilmaz MB,Biyikoglu SF,Akin Y,.Obesity is associated with impaired coronary collateral vessel development[J].Int J Obes,2003,27:1541-1545.
[35]Davignon J,Ganz P.Role of endothelial dysfunction in atherosclerosis[J].Ci rculation,2004,109:III27-32.
[36]Vanhoutte,P.M.The endothelium-modulator of vascular smooth-muscle tone[J].N Engl J Med,1988,319:512-513.
[37]Recio-Mayoral A,Banerjee D,Streather C.Endothelial dysfunction,inflammation and atherosclerosis in chronic kidney disease-a crosssectional study of predialysis,dialysis and kidney-transplantation patients[J].Atherosclerosis,2011,216:446-451.